Drug intelligence / Profile preview

AR1003

Development stage: Preclinical
Lead developer: AriBio
Administration: Oral

Overview

**AR1003** is an IND-enabling investigational combination therapy from **ARI Biotechnology** for **preclinical Alzheimer's disease**. The program is described as using a dual-mechanism approach that combines phosphodiesterase 5 inhibition with modulation or activation of the nuclear factor erythroid 2-related factor 2 pathway, aiming to support neuroprotective, cyclic guanosine monophosphate-mediated, and cellular stress-response mechanisms relevant to early Alzheimer's disease.

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on AR1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR1003.

Explore the full profile